



## MEDICAL AND RESEARCH ADVISORY COMMITTEE (MARAC)

---

### Statement from the Sickle Cell Disease Association of America Medical and Research Advisory Committee (SCDAA MARAC)

February 16, 2021 - We are aware of the announcement today from bluebird bio regarding the temporary suspension of the clinical trials of its LentiGlobin Gene Therapy for Sickle Cell Disease (bb1111). We have investigated the situation, and we have met with bluebird bio to discuss the information available to the public. MARAC is monitoring developments, and we will continue to communicate our findings to the community of people living with sickle cell disease (SCD).

SCDAA honors the SCD warriors who volunteer in clinical research. They have given their time so that others may benefit from new future treatments and cures.

We pay tribute to all of those whom we have lost to SCD, as we know many have died too young. We understand that clinical research is the path for progress to improved survival in SCD.

---

### SCDAA Medical and Research Advisory Committee Members

#### **Miguel R. Abboud, MD**

Professor of Pediatrics and Pediatric Hematology-  
Oncology  
Chairman  
Department of Pediatrics and Adolescent Medicine  
American University of Beirut, Lebanon

#### **Biree Andemariam, MD**

Vice Chair, Sickle Cell Disease Association  
of America  
Director, New England Sickle Cell Institute  
Associate Professor of Medicine  
University of Connecticut Health  
Farmington, Connecticut

#### **Shawn Bediako, PhD**

Professor  
Department of Psychology  
University of Maryland Baltimore County  
Baltimore, Maryland

#### **Andrew Campbell, MD**

Center for Cancer and Blood Disorders  
Children's National Health System  
Associate Professor of Pediatrics  
George Washington University School of Medicine and  
Health Sciences  
Washington, DC

*continued on next page*



## MEDICAL AND RESEARCH ADVISORY COMMITTEE (MARAC)

---

### Statement from the Sickle Cell Disease Association of America Medical and Research Advisory Committee (SCDAA MARAC)

February 17, 2021 - We are aware of the announcement today from bluebird bio regarding the temporary suspension of the clinical trials of its LentiGlobin Gene Therapy for Sickle Cell Disease (bb1111). We have investigated the situation, and we have met with bluebird bio to discuss the information available to the public. MARAC is monitoring developments, and we will continue to communicate our findings to the community of people living with sickle cell disease (SCD).

SCDAA honors the SCD warriors who volunteer in clinical research. They have given their time so that others may benefit from new future treatments and cures.

We pay tribute to all of those whom we have lost to SCD, as we know many have died too young. We understand that clinical research is the path for progress to improved survival in SCD.

---

### SCDAA Medical and Research Advisory Committee Members

#### **Miguel R. Abboud, MD**

Professor of Pediatrics and Pediatric Hematology-  
Oncology  
Chairman  
Department of Pediatrics and Adolescent Medicine  
American University of Beirut, Lebanon

#### **Biree Andemariam, MD**

Vice Chair, Sickle Cell Disease Association  
of America  
Director, New England Sickle Cell Institute  
Associate Professor of Medicine  
University of Connecticut Health  
Farmington, Connecticut

#### **Shawn Bediako, PhD**

Professor  
Department of Psychology  
University of Maryland Baltimore County  
Baltimore, Maryland

#### **Andrew Campbell, MD**

Center for Cancer and Blood Disorders  
Children's National Health System  
Associate Professor of Pediatrics  
George Washington University School of Medicine and  
Health Sciences  
Washington, DC

*continued on next page*

**Raffaella Colombatti, MD, PhD**

Physician Azienda Ospedaliera-Università di Padova  
Department of Womens' and Child Health  
Clinic of Pediatric Hematology Oncology  
Via Giustiniani 3 35129  
Padova, Italy

**Lori Crosby, PsyD**

Co-Director, Innovations in Community Research,  
Division of Behavioral Medicine & Clinical Psychology  
Co-Director, CCTST, Community Engagement Core  
Psychologist, Research, Behavioral Medicine & Clinical  
Psychologist  
Cincinnati Children's  
Professor, UC Department of Pediatrics  
Cincinnati, Ohio

**Deepika Darbari, MD**

Center for Cancer and Blood Disorders  
Children's National Health System  
Professor of Pediatrics  
George Washington University School of Medicine and  
Health Sciences  
Washington, DC

**Payal Desai, MD**

Associate Professor  
Director of Sickle Cell Research  
The Ohio State University  
JamesCare at Ohio State East Hospital  
Columbus, Ohio

**James Eckman, MD**

Professor Emeritus, Hematology & Medical Oncology  
Emory University School of Medicine  
Department of Hematology and Medical Oncology  
Atlanta, Georgia

**Mark Gladwin, MD**

Professor and Chair  
Department of Medicine  
Founder, Pittsburgh Heart, Lung, and Blood Vascular  
Medicine Institute  
University of Pittsburgh  
Pittsburgh, Pennsylvania

**Jo Howard, MB Bchir, MRCP, FRCPath**

Head of Red Cell/Sickle Cell Service  
Guy's and St Thomas' NHS Foundation Trust  
London, United Kingdom

**Lewis Hsu, MD, PhD**

Chair, Medical and Research Advisory Committee,  
Sickle Cell Disease Association of America  
Chief Medical Officer, Sickle Cell Disease  
Association of America  
Director of Pediatric Sickle Cell  
Professor of Pediatric Hematology-Oncology  
University of Illinois at Chicago  
Chicago, Illinois

**Baba Inusa**

Professor of Paediatric Haematology  
Lead Consultant Paediatric Sickle Cell and Thalassaemia  
Evelina London Children's Hospital  
Guy's and St Thomas' NHS Foundation Trust  
Women and Children's Academic Health  
Faculty of Life Sciences and Medicine  
King's College  
London, United Kingdom

**Elizabeth Klings, MD**

Associate Professor of Medicine  
Director, Center for Excellence in Sickle Cell  
Disease  
Director, Pulmonary Hypertension Center  
Boston University School of Medicine  
Boston, Massachusetts

**Lakshmanan Krishnamurti, MD**

Professor of Pediatrics  
Director of Bone Marrow Transplant  
Joseph Kuechenmeister Aflac Field Force Chair  
Aflac Cancer and Blood Disorders Center  
Children's Healthcare of Atlanta/Emory University  
Atlanta, Georgia

**Sophie Lanzkron, MD**

Director, Sickle Cell Center for Adults  
The Johns Hopkins Hospital  
Baltimore, Maryland

**Julie Makani, FRCP, PhD**

Associate Professor  
Department of Haematology and Blood Transfusion  
Muhimbili University of Health and Allied Sciences  
Dar es Salaam, Tanzania

**Caterina P. Minniti, MD**

Director, Sickle Cell Center Montefiore Health System  
Professor, Departments of Medicine and Pediatrics  
Albert Einstein College of Medicine  
Bronx, New York

*continued on next page*

**Genice T. Nelson, DNP, APRN, ANP-BC**

Program Director, New England Sickle Cell Institute & Connecticut Bleeding Disorders Programs, UConn Health Farmington, Connecticut  
Board Member, Sickle Cell Disease Association of America

**Isaac Odame, MB ChB, MRCP(UK), FRCPath, FRCPC, FRCPC**

Professor, Department of Paediatrics  
University of Toronto  
The Hospital for Sick Children Division of Haematology/Oncology  
Toronto, Ontario

**Kwaku Ohene-Frempong, MD**

Director Emeritus, Comprehensive Sickle Cell Center  
Emeritus Professor of Pediatrics, University of Pennsylvania  
President, Sickle Cell Foundation of Ghana  
Emeritus Board Member, Sickle Cell Disease Association of America

**Gwendolyn Poles, DO**

Former Medical Director, Kline Health Center  
Faculty, Internal Medicine Program  
UPMC Pinnacle  
Harrisburg, Pennsylvania  
Board Member, Sickle Cell Disease Association of America

**John Roberts, MD**

Yale Adult Sickle Cell Program  
Smilow Cancer Hospital at Yale New Haven  
New Haven, Connecticut

**Wally Smith, MD**

Professor  
Scientific Director, VCU Center on Health Disparities  
Director, VCU Adult Sickle Cell Program  
Department of Internal Medicine Division of General Internal Medicine  
Virginia Commonwealth University  
Richmond, Virginia

**Crawford J. Strunk MD**

Director, Sickle Cell Disease and Hemoglobinopathy Clinic  
Pediatric Hematology/Oncology Program  
ProMedica Ebeid Children's Hospital  
Toledo, Ohio

**Immacolata Tartaglione, MD PhD**

Department of Woman, Child and General and Specialist Surgery  
Università degli Studi della Campania "Luigi Vanvitelli"  
Naples, Italy

**Marsha Treadwell, PhD**

Director, Sickle Cell Care Coordination Initiative  
Regional Director, Pacific Sickle Cell Regional Collaborative  
Professor of Psychiatry and Pediatrics  
University of California San Francisco Benioff Children's Hospital Oakland  
Oakland, California

**Winfred C. Wang, MD**

Emeritus, St. Jude Faculty  
Member, Department of Hematology  
St. Jude Children's Research Hospital  
Memphis, Tennessee

**Russell E. Ware, MD, PhD**

Director, Division of Hematology  
Co-Director, Cancer and Blood Diseases Institute  
Director, Global Health Center  
Marjory J. Johnson Chair of Hematology Translational Research  
Cincinnati Children's  
Professor, UC Department of Pediatrics  
Cincinnati, Ohio

**Julie Kanter Washko, MD**

Associate Professor, Division of Hematology Oncology  
Director, Adult Sickle Cell Clinic  
University of Alabama at Birmingham  
Birmingham, Alabama

**Kim Smith-Whitley, MD**

Professor of Pediatrics  
Director, Comprehensive Sickle Cell Center  
Clinical Director, Division of Hematology  
The Children's Hospital of Philadelphia  
Philadelphia, Pennsylvania  
Board Member, Sickle Cell Disease Association of America

**Wanda Whitten-Shurney, MD**

CEO & Medical Director  
Sickle Cell Disease Association, Michigan Chapter Inc.  
Detroit, Michigan  
Board Member, Sickle Cell Disease Association of America

**Ahmar U. Zaidi, MD**

Assistant Professor of Pediatrics  
Comprehensive Sickle Cell Center, Children's Hospital of Michigan  
Director of Physician Network Development, University of Michigan  
Wayne State University/Central Michigan University School of Medicine  
Detroit, Michigan